Research programme: eye disorder therapeutics - InSite Vision

Drug Profile

Research programme: eye disorder therapeutics - InSite Vision

Alternative Names: BromDex; Bromfenac/dexamethasone ophthalmic - InSite Vision; ISV-102; ISV-215; ISV-504

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator InSite Vision
  • Class Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Prostaglandins; Small molecules; Tetracyclines
  • Mechanism of Action Cyclooxygenase inhibitors; Glucocorticoid receptor agonists; Immunosuppressants; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Ocular inflammation; Ocular pain
  • No development reported Glaucoma; Ophthalmic infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Glaucoma in USA (Ophthalmic, Drops)
  • 16 Jul 2016 No recent reports of development identified for research development in Ophthalmic-infections in USA (Ophthalmic, Drops)
  • 03 Nov 2015 InSite Vision has been acquired by Sun Pharmaceutical Industries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top